Abstract
Purpose GM1 gangliosidosis (GM1) is an ultra-rare lysosomal storage disease caused by pathogenic variants in galactosidase beta 1 (GLB1; NM_000404), primarily characterized by neurodegeneration, often in children. There are no approved treatments for GM1, but clinical trials using gene therapy (NCT03952637, NCT04713475) and small molecule substrate inhibitors (NCT04221451) are ongoing. Understanding the natural history of GM1 is essential for timely diagnosis, facilitating better supportive care, and contextualizing the results of therapeutic trials.
Methods Forty-one individuals with type II GM1 (n=17 late infantile and n=24 juvenile onset) participated in a single-site prospective observational study. Here, we describe the results of extensive multisystem assessment batteries, including clinical labs, neuroimaging, physiological exams, and behavioral assessments.
Results Classification of 37 distinct variants in this cohort was performed according to ACMG criteria and resulted in the upgrade of six and the submission of four new variants to pathogenic or likely pathogenic. In contrast to type I infantile, children with type II disease exhibited normal or near normal hearing and did not have cherry red maculae or significant hepatosplenomegaly. Some older children with juvenile onset developed thickened aortic and/or mitral valves with regurgitation. Serial MRIs demonstrated progressive brain atrophy that were more pronounced in those with late infantile onset. MR spectroscopy showed worsening elevation of myo-inositol and deficit of N-acetyl aspartate that were strongly correlated with scores on the Vineland Adaptive Behavior Scale and progress more rapidly in late infantile than juvenile onset disease.
Conclusion The comprehensive serial phenotyping of type II GM1 patients expands the understanding of disease progression and clarifies some common misconceptions about type II patients. Findings from this 10-year endeavor are a pivotal step toward more timely diagnosis and better supportive care for patients. The wealth of data amassed through this effort will serve as a robust comparator for ongoing and future therapeutic trials.
Competing Interest Statement
ALH receives consulting fees from Teladoc. The other authors declare no conflict of interest.
Funding Statement
This work was supported by the Intramural Research Program of the National Human Genome Research Institute (Tifft ZIAHG200409), the National Institute on Deafness and Other Communication Disorders, and the National Institute of Mental Health (Thurm 1ZICMH002961). This report does not represent the official view of the National Institute of Neurological Disorders and Stroke (NINDS), the National Institute on Deafness and Other Communication Disorders, the National Institute of Mental Health (NIMH), the National Human Genome Research Institute (NHGRI), the National Institutes of Health (NIH), or any part of the US Federal Government. No official support or endorsement of this article by the NINDS, NIDCD, NIMH, NHGRI, or NIH is intended or should be inferred. NCT00029965.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Institutional Review Board of the National Institutes of Health gave ethical approval for this work under protocol 02-HG-0107.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
↵* co-first authors
precilla.dsouza{at}nih.gov, cristan.farmer{at}nih.gov, jean.johnston{at}nih.gov, than{at}nygenome.org, dadams1{at}mail.nih.gov, adam.hartman{at}nih.gov, zeinw{at}nei.nih.gov, laryssa.huryn{at}nih.gov, bsolomon{at}cc.nih.gov, kingke{at}nidcd.nih.gov, Christopher.Jordan{at}inova.org, jennifer.myles{at}nih.gov, ralucanicoli{at}gmail.com, carolineerothermel{at}gmail.com, yoliann.mojica{at}gmail.com, reynahuang{at}gmail.com, rachelquimby7{at}gmail.com, mzainab2{at}vt.edu, sannebowden{at}gmail.com, anna.crowell{at}nih.gov, shu.buckley{at}nih.gov, brewerc{at}nidcd.nih.gov, dregier{at}childrensnational.org, brooksb{at}nei.nih.gov, bakere{at}cc.nih.gov, GVEZINA{at}childrensnational.org, athurm{at}mail.nih.gov, cynthiat{at}mail.nih.gov
Data Availability
The data described in this manuscript are available from the corresponding author upon reasonable request.
